Diarrhea, Pipeline Review, H1 2020 – Albireo Pharma Inc, Cosmo Pharmaceuticals, Novartis AG & Yisheng Biopharma Co Ltd – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Diarrhea – Pipeline Review, H1 2020” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Summary

The latest Pharmaceutical and Healthcare disease pipeline guide Diarrhea – Pipeline Review, H1 2020, provides an overview of the Diarrhea (Gastrointestinal) pipeline landscape.

Diarrhea is a contagious gastrointestinal infection occurring mostly due to unhygienic conditions. Diarrhea may be related to a viral or bacterial infection and is sometimes the result of food poisoning. Symptoms include nausea, abdominal pain, cramping, bloating, dehydration, fever, bloody stools, frequent urge to evacuate the bowels and incontinence. Treatment includes medication and healthy lifestyle.

Report Highlights

The Pharmaceutical and Healthcare latest pipeline guide Diarrhea – Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Diarrhea (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Diarrhea (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Diarrhea and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 13, 2, 15 and 5 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 1, 3 and 5 molecules, respectively.

Diarrhea (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from a proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope

• The pipeline guide provides a snapshot of the global therapeutic landscape of Diarrhea (Gastrointestinal).
• The pipeline guide reviews pipeline therapeutics for Diarrhea (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Diarrhea (Gastrointestinal) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Diarrhea (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Diarrhea (Gastrointestinal)

Reasons to buy

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Diarrhea (Gastrointestinal).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Diarrhea (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Key Topics Covered:

• Introduction
• Diarrhea – Overview
• Diarrhea – Therapeutics Development
• Diarrhea – Therapeutics Assessment
• Diarrhea – Companies Involved in Therapeutics Development
• Diarrhea – Drug Profiles
• Diarrhea – Dormant Projects
• Diarrhea – Discontinued Products
• Diarrhea – Product Development Milestones
• Appendix

Companies Mentioned

• Akthelia Pharmaceuticals Ltd
• Albireo Pharma Inc
• Allergan Plc
• Artugen Therapeutics Ltd
• AzurRx BioPharma Inc
• Boston Pharmaceuticals Inc
• Chongqing Zhifei Biological Products Co Ltd
• Codagenix Inc
• Cosmo Pharmaceuticals NV
• DiscoveryBiomed Inc
• Glycosyn LLC
• Immuron Ltd
• Kaleido Biosciences Inc
• Kuhnil Pharmaceutical Co Ltd
• Miyarisan Pharmaceutical Company Ltd
• MSD Wellcome Trust Hilleman Laboratories Pvt Ltd
• MyBiotics Pharma Ltd
• Napo Pharmaceuticals Inc
• Nippon Shinyaku Co Ltd
• Novartis AG
• Orphomed Inc
• Pharmascience Inc
• Prokarium Ltd
• Protagonist Therapeutics Inc
• RaQualia Pharma Inc
• Rebiotix Inc
• RedHill Biopharma Ltd
• RxBio Inc
• Scandinavian Biopharma Holding AB
• Synthetic Biologics Inc
• Syntiron LLC
• VenatoRx Pharmaceuticals Inc
• Yisheng Biopharma Co Ltd

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/9yg2js

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900